Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (VISNU-1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01640405|
Recruitment Status : Completed
First Posted : July 13, 2012
Last Update Posted : April 11, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Colorectal Cancer||Drug: modified FOLFOX6 + bevacizumab Drug: FOLFOXIRI + Bevacizumab||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||350 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.|
|Actual Study Start Date :||July 2012|
|Actual Primary Completion Date :||November 2018|
|Actual Study Completion Date :||November 2018|
Active Comparator: Control
modified FOLFOX6 + bevacizumab
Drug: modified FOLFOX6 + bevacizumab
Drug: FOLFOXIRI + Bevacizumab
- Progression free survival (PFS) [ Time Frame: 5 years ]
- Overall survival (OS) [ Time Frame: 5 years ]
- Response rate (RR) [ Time Frame: 5 years ]
- Radical Resection (R0) surgery rate [ Time Frame: 5 years ]
- Circulating Tumour Cells (CTC) count basal and correlate to PFS, OS, RR [ Time Frame: 5 years ]
- Correlation of RAS, BRAF and PI3K mutations and clinical anti-tumour activity outcome ( PFS, OS, RR) [ Time Frame: 5 years ]
- Adverse events [ Time Frame: 5 years ]
- Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR) [ Time Frame: 5 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patient's Informed consent in written.
- Age between 18 and 70 years old.
- Eastern Cooperative Oncology group performance status (ECOG) 0-1.
- Life expectancy of at least 3 months.
- Histological confirmation of adenocarcinoma of the colon or rectum.
- To be included in the study patients should present > or equal 3 CTC in peripheral blood.
- Measurable metastatic stage IV disease with at least 1 measurable metastatic lesion following Response Evaluation Criteria In Solid Tumors (RECIST) criteria v 1.1 (non suitable for radical surgery at the inclusion time).
- Prior radiotherapy is allowed but must be completed at least 4 weeks before randomization (if applicable).
- Adequate bone marrow, liver and renal function.
- Women of childbearing potential must have a negative serum or urine pregnancy test. Postmenopausal women must have been amenorrheic for at least 12 months.Both men and women participating in this study must use adequate contraception.
- Subject must have the ability, in the opinion of the investigator, to comply with all the study procedures and follow-up examinations.
- Previous chemotherapy for metastatic disease.
- Prior treatment with Bevacizumab, or Epidermal Growth Factor Reception (EGFR) inhibitors
- Any anticancer treatment (chemotherapy, hormonal treatment, radiation treatment, surgery , immunotherapy, biologic therapy or tumour embolization) within 4 weeks before randomization.
- Use of any investigational drug within 4 weeks before start the treatment
- Clinical or radiographic evidence of brain metastasis.
- Uncontrolled hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg on repeated measurement) despite optimal medical management.
- Previous history of hypertensive encephalopathy or hypertensive crises.
- Current or history of peripheral neuropathy > or equal to 1 National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE).
- Patients classified as fragile according to criteria listed in the protocol.
- Significant cardiovascular disease (e.g. cerebrovascular accident (CVA), myocardial infarction, within 6 months before randomization). Unstable angina, congestive heart failure New York Heart Association (NYHA) ≥ class II, arrhythmia that requires treatment within 3 months before randomization.
- Significant vascular disease (e.g. aortic aneurism requiring surgical intervention, pulmonary embolic, peripheral arterial thrombosis) within 6 months before randomization.
- Previous history of significant haemorrhage /severe, within 1 month before randomization.
- Major surgery, open surgical biopsy or significant traumatic injury within 4 weeks before randomization.
- Large bore needle biopsy of a major organ within 14 days before randomization. Placement of central venous access port > or equal to 7 days before randomization is permitted
- Evidence or history of bleeding diathesis or coagulopathy.
- International Normalized Ratio (INR) > 1.5 within 14 days prior to starting study treatment. EXEMPTION: patients on full anticoagulation must have an in-range INR [usually between 2-3]. Any anticoagulation therapy must be at stable dosing prior to enrollment.
- History of previous abdominal fistula or gastrointestinal perforation within 6 months before randomization.
- Serious non-healing wound, ulcer or bone fracture.
- Acute or sub-acute of intestinal occlusion or history of intestinal inflammatory disease.
- History of uncontrolled convulsive crises.
- History of pulmonary fibrosis, acute lung disease or interstitial pneumonia.
- Chronic, actual o recent use (10 days prior first drug administration) of acetylsalicylic acic (aspirin) > 325 mg/day or clopidogrel (75mg/day) or other treatments that can cause gastrointestinal ulcer (low-dose aspirin is permitted < or equal to 325 mg/day).
- Urinary protein excretion > or equal to 2+ (dipstick). If > or equal 2 g proteinuria is detected with dipstick, a 24-hour period urine test will be performed and the result should be < or equal to 1 g/24 hours to permit the inclusion of the patient in the clinical trial.
- Known human immunodeficiency virus infection or chronic hepatitis B or C infection or other uncontrolled, severe concurrent infection .
- Current infection > or equal to Grade 2 (NCI-CTCAE).
- Any previous or concurrent cancer different to colorectal carcinoma within 5 years before to start the treatment. Subjects with successfully treated, non-invasive cancers, including cervical cancer in situ, basal cell carcinoma will be allowed to participate in the clinical trial. Or those cancer treated with curative intention without disease evidence in the last 5 years at least.
- Known or suspected allergy or hypersensitivity to any component of Bevacizumab, oxaliplatin, irinotecan, or 5-FU/LV.
- Any medical, psychological, or social condition that may interfere with the subject's participation in the study or evaluation of the study results.
- Any psychological, familial or geographic situation that interferes in the adequate follow.up and adherence to the study protocol.
- Women who are pregnant or breast-feeding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01640405
|Spanish Cooperative Group for Digestive Tumour Therapy|
|Madrid, Spain, 28046|
|Study Chair:||Eduardo Díaz-Rubio, MD-PhD||Hospital San Carlos, Madrid|
|Study Chair:||Enrique Aranda, MD-PhD||Hospital Reina Sofía|
|Study Chair:||Javier Sastre, MD-PhD||Hospital San Carlos, Madrid|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|
|Other Study ID Numbers:||
2012-000846-37 ( EudraCT Number )
|First Posted:||July 13, 2012 Key Record Dates|
|Last Update Posted:||April 11, 2019|
|Last Verified:||April 2019|
circulating tumor cell
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Antineoplastic Agents, Immunological
Angiogenesis Modulating Agents
Physiological Effects of Drugs